Market Cap 230.73M
Revenue (ttm) 742.90M
Net Income (ttm) 52.60M
EPS (ttm) N/A
PE Ratio 3.19
Forward PE N/A
Profit Margin 7.08%
Debt to Equity Ratio 1.70
Volume 746,200
Avg Vol 1,048,306
Day's Range N/A - N/A
Shares Out 51.27M
Stochastic %K 19%
Beta 2.35
Analysts Strong Sell
Price Target $10.00

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botul...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 631 3200
Fax: 240 631 3203
Address:
300 Professional Drive, Suite 400, Gaithersburg, United States
CoffeeRocks
CoffeeRocks Aug. 19 at 12:59 AM
$EBS No longer with EBS ☝️
1 · Reply
USAEquityResearch
USAEquityResearch Aug. 19 at 12:33 AM
$EBS 📊 USAEquityResearch ▲ 4.66 (+3.56%) Trend: Bearish 📉 RSI (14): 17.4 — oversold, potential bounce territory MACD: bearish, below signal line Volume: below average 📌 Key Levels Resistance: 7.69 Support: 4.45 20-MA: 6.19 | 50-MA: 7.35 Educational content only. Not financial advice.
0 · Reply
WinstonSmith33
WinstonSmith33 Aug. 18 at 10:34 PM
$EBS You are delusional like others. Lindahl was here before, after and during covid. He's not new here. He IS responsible for death spiral from 140$ to 1.42$ and for wasting millions of vaccines. He should have left after the Kramer scandal as well (Emergent paid for insider trading of its ex-CEO, yes in fact we paid for that). Cyfendus order is not certain and other contracts already showed us that Trump cares about nothing. https://www.fiercepharma.com/pharma/former-emergent-ceo-kramer-faces-insider-trading-allegations-ny
2 · Reply
Nuesta
Nuesta Aug. 18 at 9:52 PM
$EBS I have analyzed this stock / company to death. Government procurement is lumpy, BUT the government is transparent. I have built an inventory replacement schedule and how it could impact ENITDA, monitored the key execs specified in the CYFENDUS contract to see if they are still at EBS, same for the sales team - are they abandoning ship because there is little hope of commissions… They are all still there. When I connect the dots, I see a different story where MCM is the recurring revenue machine that drives growth. But, I can equally see the negative side of the story due to decrease in NARCAN sales and possible credit issues. It will come down to the timing of the CYFENDUS contract renewal. As Arthur Wellesley said of Waterloo, ‘it was the nearest run thing you ever saw in your life.’ (Waterloo 18 June 1815)
1 · Reply
Nuesta
Nuesta Aug. 18 at 9:38 PM
$EBS Does there CFO have the background to navigate this finance tightrope? Richard Lindahl’s background is actually unusually relevant to the problem EBS faces now. He was CFO through the company's restructuring and asset sales, and in January 2026 EBS prepaid its previous term loan; then in April it put the new OrbiMed financing structure in place. There's another interesting supporting piece: EBS recently added Neal Fowler to the board. Fowler spent 14 years at Wells Fargo Securities in senior corporate/investment-banking roles and previously headed healthcare banking at JPMorgan and Salomon Brothers. So Lindahl isn't navigating the capital structure in isolation, the board now contains substantial financing expertise. This all comes down to timing, which is why the CYFENDUS contract is so important.
0 · Reply
Nuesta
Nuesta Aug. 18 at 9:38 PM
$EBS If EBS remains comfortably liquid, a falling bond price can actually create an attractive deleveraging opportunity. The math is straightforward. Suppose EBS's 2028 notes fell to: * 93¢: $75M cash retires about $80.6M face value. * 85¢: $75M retires about $88.2M. * 80¢: $75M retires about $93.8M. * 70¢: $75M retires about $107.1M. And EBS gets two benefits: it removes more principal than the cash it spends, and eliminates the interest expense on that retired principal. It also recognizes an accounting gain when debt is extinguished below par. EBS already demonstrated this in 2025: it retired $10.3M face value for about $8.7M cash and recorded roughly a $1.6M gain.
0 · Reply
Nuesta
Nuesta Aug. 18 at 9:37 PM
$EBS S&P revised EBS's credit outlook today from stable to negative, while affirming the company's B- issuer rating and CCC+ rating on the 2028 unsecured notes. The distinction is important: S&P did not downgrade the actual rating. But it is warning that the trajectory has become riskier. There is, however, an interesting positive item that is buried in the credit analysis. S&P estimates EBS had approximately $280M of cash in July, helped by strong AR collections, plus full availability on its $50M ABL. And S&P specifically notes the company's authorization to repurchase $75M of the notes and says additional cash could be used to reduce debt ahead of refinancing. EBS's SEC filing confirms the $75M note repurchase authorization.
0 · Reply
westparktrader
westparktrader Aug. 18 at 8:54 PM
$EBS Nobody screams for REVIVE , REXTOVY or OPVEE Its NARCAN give her the SHOT!!
0 · Reply
frankinsense69
frankinsense69 Aug. 18 at 4:34 PM
$EBS Utter clown
0 · Reply
StockTwitsGhost
StockTwitsGhost Aug. 18 at 3:09 PM
$EBS What happened here. Still own a small position but haven't been tracking cmosely.
2 · Reply
Latest News on EBS
Emergent BioSolutions Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 13 days ago

Emergent BioSolutions Earnings Call Transcript: Q2 2026


Emergent BioSolutions Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 13 days ago

Emergent BioSolutions Earnings release: Q2 2026


Emergent BioSolutions Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 13 days ago

Emergent BioSolutions Slides: Q2 2026


Emergent BioSolutions Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 13 days ago

Emergent BioSolutions Quarterly report: Q2 2026


Emergent BioSolutions awarded $52.7M contract modification

2026-06-29T13:25:30.000Z - 7 weeks ago

Emergent BioSolutions awarded $52.7M contract modification


Emergent BioSolutions awarded $64.5M HHS contract modification

2026-05-28T21:00:59.000Z - 2 months ago

Emergent BioSolutions awarded $64.5M HHS contract modification


Emergent BioSolutions Earnings Call Transcript: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 3 months ago

Emergent BioSolutions Earnings Call Transcript: Q1 2026


Emergent BioSolutions Earnings release: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 3 months ago

Emergent BioSolutions Earnings release: Q1 2026


Emergent BioSolutions Slides: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 3 months ago

Emergent BioSolutions Slides: Q1 2026


Emergent BioSolutions Quarterly report: Q1 2026

Apr 30, 2026, 5:00 PM EDT - 3 months ago

Emergent BioSolutions Quarterly report: Q1 2026


Emergent BioSolutions Transcript: AGM 2026

Apr 29, 2026, 9:00 AM EDT - 4 months ago

Emergent BioSolutions Transcript: AGM 2026


Emergent BioSolutions Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing


Emergent BioSolutions Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing


Emergent BioSolutions Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing


Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing


Emergent BioSolutions Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Emergent BioSolutions Proxy statement: Proxy filing


Emergent BioSolutions Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing


Emergent BioSolutions Proxy statement: Proxy filing

Mar 20, 2026, 8:00 AM EDT - 5 months ago

Emergent BioSolutions Proxy statement: Proxy filing


Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

Mar 17, 2026, 12:49 PM EDT - 5 months ago

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

SIGA


Emergent BioSolutions appoints Fowler to board of directors

2026-03-03T13:40:58.000Z - 6 months ago

Emergent BioSolutions appoints Fowler to board of directors


Emergent BioSolutions appoints Fowler to board of directors

2026-03-03T13:27:16.000Z - 6 months ago

Emergent BioSolutions appoints Fowler to board of directors


Emergent BioSolutions Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Earnings Call Transcript: Q4 2025


Emergent BioSolutions Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Annual report: Q4 2025


Emergent BioSolutions Earnings release: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Earnings release: Q4 2025


Emergent BioSolutions Slides: Q4 2025

Feb 26, 2026, 5:00 PM EST - 6 months ago

Emergent BioSolutions Slides: Q4 2025


Emergent BioSolutions Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Earnings Call Transcript: Q3 2025


Emergent BioSolutions Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Quarterly report: Q3 2025


Emergent BioSolutions Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Earnings release: Q3 2025


Emergent BioSolutions Slides: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 10 months ago

Emergent BioSolutions Slides: Q3 2025


Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 4:15 PM EDT - 10 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results


CoffeeRocks
CoffeeRocks Aug. 19 at 12:59 AM
$EBS No longer with EBS ☝️
1 · Reply
USAEquityResearch
USAEquityResearch Aug. 19 at 12:33 AM
$EBS 📊 USAEquityResearch ▲ 4.66 (+3.56%) Trend: Bearish 📉 RSI (14): 17.4 — oversold, potential bounce territory MACD: bearish, below signal line Volume: below average 📌 Key Levels Resistance: 7.69 Support: 4.45 20-MA: 6.19 | 50-MA: 7.35 Educational content only. Not financial advice.
0 · Reply
WinstonSmith33
WinstonSmith33 Aug. 18 at 10:34 PM
$EBS You are delusional like others. Lindahl was here before, after and during covid. He's not new here. He IS responsible for death spiral from 140$ to 1.42$ and for wasting millions of vaccines. He should have left after the Kramer scandal as well (Emergent paid for insider trading of its ex-CEO, yes in fact we paid for that). Cyfendus order is not certain and other contracts already showed us that Trump cares about nothing. https://www.fiercepharma.com/pharma/former-emergent-ceo-kramer-faces-insider-trading-allegations-ny
2 · Reply
Nuesta
Nuesta Aug. 18 at 9:52 PM
$EBS I have analyzed this stock / company to death. Government procurement is lumpy, BUT the government is transparent. I have built an inventory replacement schedule and how it could impact ENITDA, monitored the key execs specified in the CYFENDUS contract to see if they are still at EBS, same for the sales team - are they abandoning ship because there is little hope of commissions… They are all still there. When I connect the dots, I see a different story where MCM is the recurring revenue machine that drives growth. But, I can equally see the negative side of the story due to decrease in NARCAN sales and possible credit issues. It will come down to the timing of the CYFENDUS contract renewal. As Arthur Wellesley said of Waterloo, ‘it was the nearest run thing you ever saw in your life.’ (Waterloo 18 June 1815)
1 · Reply
Nuesta
Nuesta Aug. 18 at 9:38 PM
$EBS Does there CFO have the background to navigate this finance tightrope? Richard Lindahl’s background is actually unusually relevant to the problem EBS faces now. He was CFO through the company's restructuring and asset sales, and in January 2026 EBS prepaid its previous term loan; then in April it put the new OrbiMed financing structure in place. There's another interesting supporting piece: EBS recently added Neal Fowler to the board. Fowler spent 14 years at Wells Fargo Securities in senior corporate/investment-banking roles and previously headed healthcare banking at JPMorgan and Salomon Brothers. So Lindahl isn't navigating the capital structure in isolation, the board now contains substantial financing expertise. This all comes down to timing, which is why the CYFENDUS contract is so important.
0 · Reply
Nuesta
Nuesta Aug. 18 at 9:38 PM
$EBS If EBS remains comfortably liquid, a falling bond price can actually create an attractive deleveraging opportunity. The math is straightforward. Suppose EBS's 2028 notes fell to: * 93¢: $75M cash retires about $80.6M face value. * 85¢: $75M retires about $88.2M. * 80¢: $75M retires about $93.8M. * 70¢: $75M retires about $107.1M. And EBS gets two benefits: it removes more principal than the cash it spends, and eliminates the interest expense on that retired principal. It also recognizes an accounting gain when debt is extinguished below par. EBS already demonstrated this in 2025: it retired $10.3M face value for about $8.7M cash and recorded roughly a $1.6M gain.
0 · Reply
Nuesta
Nuesta Aug. 18 at 9:37 PM
$EBS S&P revised EBS's credit outlook today from stable to negative, while affirming the company's B- issuer rating and CCC+ rating on the 2028 unsecured notes. The distinction is important: S&P did not downgrade the actual rating. But it is warning that the trajectory has become riskier. There is, however, an interesting positive item that is buried in the credit analysis. S&P estimates EBS had approximately $280M of cash in July, helped by strong AR collections, plus full availability on its $50M ABL. And S&P specifically notes the company's authorization to repurchase $75M of the notes and says additional cash could be used to reduce debt ahead of refinancing. EBS's SEC filing confirms the $75M note repurchase authorization.
0 · Reply
westparktrader
westparktrader Aug. 18 at 8:54 PM
$EBS Nobody screams for REVIVE , REXTOVY or OPVEE Its NARCAN give her the SHOT!!
0 · Reply
frankinsense69
frankinsense69 Aug. 18 at 4:34 PM
$EBS Utter clown
0 · Reply
StockTwitsGhost
StockTwitsGhost Aug. 18 at 3:09 PM
$EBS What happened here. Still own a small position but haven't been tracking cmosely.
2 · Reply
BavarianStallion
BavarianStallion Aug. 18 at 1:04 PM
$EBS Not good if they use it and it doesn‘t work
1 · Reply
KnuckleSandwich
KnuckleSandwich Aug. 18 at 1:02 AM
$EBS Hey Papa you can’t buy this kind of or for Narcan awareness https://pagesix.com/2026/08/17/celebrity-news/narcan-found-at-scene-of-hayden-panettieres-apparent-overdose/
0 · Reply
KnuckleSandwich
KnuckleSandwich Aug. 18 at 12:58 AM
$EBS Narcan was found at scene https://www.facebook.com/story.php?story_fbid=1688856482598736&id=extra
0 · Reply
KnuckleSandwich
KnuckleSandwich Aug. 18 at 12:41 AM
$EBS Hayden Panettiere overdose… Narcan was found at the scene.. Maybe EBS can get some public traction on how critical it is to increase accessibility
0 · Reply
CoffeeRocks
CoffeeRocks Aug. 17 at 9:35 PM
$EBS https://www.ross-shirejournal.co.uk/news/youtuber-documents-his-survival-of-deadly-anthrax-island-442719/
0 · Reply
tuningin
tuningin Aug. 17 at 2:58 PM
$EBS dang son. C’mon
0 · Reply
SignoreRossi
SignoreRossi Aug. 17 at 12:47 PM
$EBS 3 this week or next?
2 · Reply
CoffeeRocks
CoffeeRocks Aug. 17 at 12:15 PM
$EBS $CODX $AEMD $GOVX $VRAX https://share.google/URauLdlDxl7AA4l9k
0 · Reply
CoffeeRocks
CoffeeRocks Aug. 17 at 12:50 AM
$EBS https://www.mysanantonio.com/news/local/article/texas-anthrax-goat-22388416.php
0 · Reply
CoffeeRocks
CoffeeRocks Aug. 17 at 12:49 AM
$EBS https://share.google/dFL5HKbaG7zDJbFjH
0 · Reply
westparktrader
westparktrader Aug. 16 at 1:09 PM
$EBS mpox vaccine made by bavarian nordic is the recommended in USA but this article tells a diff story https://www.thefocalpoints.com/p/bavarian-nordics-jynneos-monkeypox
1 · Reply
ComradeKomisar
ComradeKomisar Aug. 15 at 10:23 PM
$EBS 13F tally as of Q2 '26. Institutions have actually increased their stake, driven by hedge funds. Of the latter, Marshal Wace and Pacer have completely checked out. Millenium has increased its stake.
2 · Reply